Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of CNTN3 protein in prognosis judgement of neuroglioma

A technique for judging the prognosis of glioma, applied in the field of clinical medicine, to achieve the effect of improving the survival rate of patients, profound clinical significance, and improving the quality of life after surgery

Pending Publication Date: 2019-08-27
朱义芳 +1
View PDF2 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

But so far, there is no clinically applicable molecular marker that can accurately predict the prognosis of glioma patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CNTN3 protein in prognosis judgement of neuroglioma
  • Application of CNTN3 protein in prognosis judgement of neuroglioma
  • Application of CNTN3 protein in prognosis judgement of neuroglioma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] This example provides the application research of CNTN3 mRNA expression in the prognosis evaluation of human glioma, as follows:

[0026] Patient samples: The present invention involves microarray and sequencing results of 317 cases of glioma and 32 cases of normal brain tissue. Among them, the expression profile chip GSE4290 included 81 cases of glioma and 23 cases of normal brain tissue, and the expression profile chip GSE7696 included 80 cases of glioma and 4 cases of normal brain tissue, which were obtained from the GEO database (https: / / www.ncbi. nlm.nih.gov / geo / ); Another 156 cases of glioma and 5 cases of normal brain tissue sequencing data and detailed clinical information data come from the Tumor Genome Atlas (TCGA) (https: / / cancergenome.nih.gov / ). The overall survival time was defined as the time from the diagnosis of glioma to the death of the patient or the end of follow-up.

[0027] Analysis method: Download chip and sequencing data compression packages ...

Embodiment 2

[0037] This example gives the application research of CNTN3 protein expression in the prognosis evaluation of human glioma, as follows:

[0038] Patient samples: tissue chips from Shanghai Xinchao Biotechnology Co., Ltd. (product number: HBraG080PG01), including 13 normal brain tissues and 67 glioma tissue samples.

[0039]Detection method: Bake the front side of the tissue chip in a 65°C oven for 40 minutes to make the specimen adhere better, immerse in xylene washing tanks I, II, and III, and place them in a constant temperature water bath at 25°C for 10 minutes. Transfer to 100%, 85%, and 75% ethanol for gradient hydration for 3 minutes each, then transfer to PBS buffer I, II, III for 5 minutes each time, place in 3% hydrogen peroxide washing tank for 15 minutes, and block the endogenous sex peroxidase. Immerse in the heated sodium citrate buffer, and microwave for 20 minutes on low heat. Immerse in PBS buffer I, II, III for 3 minutes each time. Draw the area along the e...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses usages of CNTN3 protein, application of the CNTN3 protein in preparation of drugs for diagnosis and prognosis judgement or treatment of neuroglioma, and application of mRNA encoding the CNTN3 protein in preparation of the drugs for diagnosis and prognosis judgement or treatment of neuroglioma. By detecting the CNTN3 protein / mRNA in a tissue sample, the prognosis of a gliomapatient can be judged effectively. The usages of the CNTN3 protein disclosed by the invention can provide strong technical support for prognosis analysis of a neuroglioma patient, are beneficial fora clinician to choose a reasonable subsequent therapeutic schedule, improve postoperative living quality of the neuroglioma patient, increase survival rate of the patient, have profound clinical significance, and are suitable for clinical popularization and application.

Description

technical field [0001] The invention relates to the technical field of clinical medicine, in particular to an application of CNTN3 protein in judging the prognosis of glioma. Background technique [0002] Glioma is the most common tumor of the nervous system, accounting for about 80% of brain tumors. The average number of newly diagnosed cases per year is about 17,000. not optimistic. The survival time of most glioma patients is 12-15 months, and only 3-5% of patients can survive for more than 5 years. There are many factors that affect the prognosis of patients. It is generally accepted that factors such as patient age, tumor size, tumor grade, KPS score, degree of surgical resection, postoperative radiotherapy dose, and application of temozolomide have a predictive effect on patient prognosis, but there is no conclusion yet. Changes in the levels of certain genes or proteins in cells may be the motivating factors of glioma formation or the markers of patient prognosis. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/6886C12N15/11G01N33/574G01N33/53
CPCC12Q1/6886G01N33/57407G01N33/53C12Q2600/158C12Q2600/118
Inventor 朱义芳刘华伟
Owner 朱义芳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com